英国老年人他汀治疗的终身效果与成本效益:一项模型研究
该建模研究基于CTTC和英国生物银行队列开发的CVD微模拟模型,评估≥70岁人群终身标准或高强度他汀治疗的效果与成本效益。结果显示标准他汀每人增加0.24-0.70 QALYs,高强度他汀额外增加0.04-0.13 QALYs,增量成本效果比分别低于£3502/QALY和£11778/QALY,具有成本效益。
要点
- ≥70岁无或有CVD者终身标准他汀增加0.24-0.70 QALYs,高强度他汀额外增加0.04-0.13 QALYs。
- 标准他汀增量成本低于£3502/QALY,高强度他汀低于£11778/QALY,具成本效益。
- 无CVD的老年人中他汀成本效益不确定性较大,但敏感性分析仍具成本效益。
核心结论
- 基于当前他汀疗效证据和建模分析,≥70岁男性和女性接受他汀治疗可改善健康结局且具成本效益。
研究设计与样本
- 使用基于CTTC和英国生物银行队列开发的CVD微模拟模型,在UK Biobank和Whitehall II研究中≥70岁参与者中评估模型性能。
- 模型预测终身标准他汀(LDL-C降低35%-45%)或高强度他汀(降低≥45%)的心血管风险、生存、QALYs和医疗成本(2021年英镑)。
- 分析纳入UK Biobank中≥70岁无CVD者15,019例和有CVD者5,103例。
主要发现
- 终身标准他汀每人增加0.24-0.70 QALYs,高强度他汀额外增加0.04-0.13 QALYs。
- 标准他汀增量成本低于£3502/QALY,高强度他汀低于£11778/QALY,具高概率成本效益。
- 敏感性分析中他汀仍具成本效益,但无CVD老年人的成本效益不确定性较大。
临床怎么用
- 对于≥70岁男性和女性,可考虑终身标准或高强度他汀治疗以改善健康结局并具成本效益。
局限性
- 无CVD的老年人中他汀成本效益不确定性较大。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cardiovascular disease (CVD) risk increases with age. Statins reduce cardiovascular risk but their effects are less certain at older ages. We assessed the long-term effects and cost-effectiveness of statin therapy for older people in the contemporary UK population using a recent meta-analysis of randomised evidence of statin effects in older people and a new validated CVD model. METHODS: The performance of the CVD microsimulation model, developed using the Cholesterol Treatment Trialists' Collaboration (CTTC) and UK Biobank cohort, was assessed among participants ≥70 years old at (re)surveys in UK Biobank and the Whitehall II studies. The model projected participants' cardiovascular risks, survival, quality-adjusted life years (QALYs) and healthcare costs (2021 UK£) with and without lifetime standard (35%-45% low-density lipoprotein cholesterol reduction) or higher intensity (≥45% reduction) statin therapy. CTTC individual participant data and other meta-analyses informed statins' effects on cardiovascular risks, incident diabetes, myopathy and rhabdomyolysis. Sensitivity of findings to smaller CVD risk reductions and to hypothetical further adverse effects with statins were assessed. RESULTS: In categories of men and women ≥70 years old without (15,019) and with (5,103) prior CVD, lifetime use of a standard statin increased QALYs by 0.24-0.70 and a higher intensity statin by a further 0.04-0.13 QALYs per person. Statin therapies were cost-effective with an incremental cost per QALY gained below £3502/QALY for standard and below £11778/QALY for higher intensity therapy and with high probability of being cost-effective. In sensitivity analyses, statins remained cost-effective although with larger uncertainty in cost-effectiveness among older people without prior CVD. CONCLUSIONS: Based on current evidence for the effects of statin therapy and modelling analysis, statin therapy improved health outcomes cost-effectively for men and women ≥70 years old.
引用
- Mihaylova B, Wu R, Zhou J, et al. Lifetime effects and cost-effectiveness of statin therapy for older people in the United Kingdom: a modelling study. Heart. 2024. PMID: 39256053. doi:10.1136/heartjnl-2024-324052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。